Scientists have created a highly specific and well-characterised chemical probe which can switch off two important proteins implicated in cancer -- shedding new light on the role these proteins play in driving cancer cell proliferation.
A major new study, published in Nature Chemical Biology today (Monday), announces the discovery of the first highly selective modulator of two proteins called CDK8 and CDK19 -- members of an important family known as kinases -- whose function is to regulate gene activation.
This well-characterised chemical probe will allow more precise analysis than ever before of the biological the roles of CDK8 and CDK19 in cancer and other cells.
The study comes from a research partnership between The Institute of Cancer Research, London, the University of Cardiff, pharmaceutical company Merck Serono, and Cancer Research Technology -- the commercial arm of Cancer Research UK, which was one of the study's funders.
The chemical probe (CCT251545) - published by the same team earlier this year -- was discovered by screening a large collection of chemicals against the WNT signalling pathway in cancer cells.
In the new study, the team describe the discovery that CDK8 and CDK19 are the biochemical targets of CCT251545.
The researchers report their work using a range of biological and biophysical techniques to show that CCT251545 potently and selectively binds to CDK8 and CDK19. They go on to explain how the probe binds to CDK8 and CDK19 and how this in turn blocks the WNT signalling pathway, a known driver of many bowel cancers.
Study co-leader Professor Julian Blagg, Deputy Director of the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, said:
"This collaborative study describes our detailed characterisation of CCT251545 as a highly specific chemical probe for the kinases CDK8 and CDK19 that control gene activation. Publishing our work will enable the scientific community to use our probes to further explore the role of these closely related proteins in cancer and other diseases."
Study co-leader Professor Trevor Dale, Deputy Head of Molecular Biosciences at Cardiff University, said:
"This study is a superb example of how an inter-disciplinary team of scientists from academia and industry can cooperate to produce work of the highest quality. It is great to look back and see how much was achieved."
Fellow study author Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:
"The discovery of this new, highly specific chemical probe could help us to shed new light on an important pathway in cancer -- and in biology generally -- and help researchers to understand how to influence and exploit it.
"Chemical probes are very important tools in the development of new drugs, because they allow us to explore the effect of blocking cancer-causing proteins in cells. Our discovery through collaborative team science of highly potent, selective inhibitors for cancer proteins addresses an important need to find such probes for the huge area of the cancer signalling network that is still largely unexplored."
###
Notes to editors
For more information please contact Henry French
020-7153-5282
henry.french@icr.ac.uk
For enquiries out of hours, please call 07595 963613.
The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes.
Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden NHS Foundation Trust and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.
The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.
The ICR's mission is to make the discoveries that defeat cancer. For more information visit http://www.icr.ac.uk
About Cancer Research UK
- Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
- Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
- Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
- Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last forty years.
- Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that 3 in 4 people will survive their cancer for at least 10 years within the next 20 years.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit http://www.cancerresearchuk.org.
Cardiff University
Cardiff University is recognised in independent government assessments as one of Britain's leading teaching and research universities and is a member of the Russell Group of the UK's most research intensive universities. The 2014 Research Excellence Framework ranked the University 5th in the UK for research excellence. Among its academic staff are two Nobel Laureates, including the winner of the 2007 Nobel Prize for Medicine, University Chancellor Professor Sir Martin Evans. Founded by Royal Charter in 1883, today the University combines impressive modern facilities and a dynamic approach to teaching and research. The University's breadth of expertise encompasses: the College of Arts, Humanities and Social Sciences; the College of Biomedical and Life Sciences; and the College of Physical Sciences and Engineering, along with a longstanding commitment to lifelong learning. Cardiff's flagship Research Institutes are offering radical new approaches to pressing global problems. http://www.cardiff.ac.uk
Journal
Nature Chemical Biology